Project Grant K08DK149188
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $156K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $889,856 on August 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms by which metabolic-associated fatty liver disease (MASH) drives chronic kidney disease pathogenesis. The recipient will conduct three specific research aims over the performance period through April 30, 2031. Aim 1 confirms the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $874,673 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how suppression of 5-aminolevulinic acid synthase 1 (ALAS1) enhances therapeutic RNA interference activity. The project tests a novel genetic strategy to improve the efficacy of small interfering RNAs (siRNAs) in extrahepatic tissues where...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $726,142 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of microbiota-specific T cells in inflammatory bowel disease. The research uses deep single-cell RNA and T cell receptor sequencing technologies to longitudinally profile T cell repertoire and phenotype in two parallel studies: human...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $571,200 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on mechanisms protecting pancreatic beta cells from dysfunction and death in diabetes. The award funds research into a novel small molecule compound (Compound 43) that acts as a molecular glue to stabilize the interaction between the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $816,825 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how injured podocytes communicate with parietal epithelial cells to drive proliferative glomerulopathy, specifically whether podocyte-derived exosomes mediate this cell-to-cell signaling in rapidly progressive glomerulonephritis. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $168,000 on May 7, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research targeting ChREBPβ for beta-cell protection in Type 1 diabetes. The research characterizes the contribution of ChREBPβ (carbohydrate-responsive element-binding protein B), a stress-inducible transcription factor, to beta-cell dysfunction in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beth Israel Deaconess Medical Center $164,484 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DNAJC22 in metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research exploring DNAJC22, a gene of unknown function identified through genome-wide CRISPR-Cas9 screening and human genetic association studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $910,670 to Icahn School of Medicine at Mount Sinai on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize a cluster of single-nucleotide polymorphisms (SNPs) in the LILRB3 gene associated with post-transplant renal failure in kidney transplant recipients. The research characterizes four consecutive SNPs in LILRB3 that encode missense mutations...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Baylor College of Medicine $167,165 on July 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate molecular mechanisms of T cell dysfunction in pediatric chronic cholestatic liver diseases. The research program, spanning five years through March 31, 2031, and performed in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $874,741 on June 1, 2026, to investigate transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research identifies and characterizes transcription factors that regulate collagen production in hepatic stellate cells, a key driver of liver...